Abivax Statistics

Total Valuation

Abivax has a market cap or net worth of $872.67 million. The enterprise value is $676.24 million.

Market Cap	872.67M
Enterprise Value	676.24M

Important Dates

The last earnings date was Tuesday, April 2, 2024, before market open.

Earnings Date	Apr 2, 2024
Ex-Dividend Date	n/a

Share Statistics

Abivax has 62.92 million shares outstanding.

Shares Outstanding	62.92M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+19.95%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	1.76%
Float	22.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	170.94
Forward PS	n/a
PB Ratio	4.15
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	131.71
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.38.

Current Ratio	4.08
Quick Ratio	n/a
Debt / Equity	0.38
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-4.30

Financial Efficiency

Return on equity (ROE) is -145.40% and return on invested capital (ROIC) is -47.09%.

Return on Equity (ROE)	-145.40%
Return on Assets (ROA)	-73.40%
Return on Capital (ROIC)	-47.09%
Revenue Per Employee	$84,171
Profits Per Employee	-$2.69M
Employee Count	61
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (1Y)	1.37
52-Week Price Change	n/a
50-Day Moving Average	14.67
200-Day Moving Average	n/a
Relative Strength Index (RSI)	38.54
Average Volume (30 Days)	66,196

Short Selling Information

The latest short interest is 64,846, so 0.10% of the outstanding shares have been sold short.

Short Interest	64,846
Short Previous Month	113,774
Short % of Shares Out	0.10%
Short % of Float	0.28%
Short Ratio (days to cover)	0.63

Income Statement

In the last 12 months, Abivax had revenue of $5.13 million and -$164.16 million in losses. Loss per share was -$3.70.

Revenue	5.13M
Gross Profit	4.99M
Operating Income	-137.47M
Pretax Income	-159.45M
Net Income	-164.16M
EBITDA	-128.60M
EBIT	-129.36M
Loss Per Share	-$3.70

Full Income Statement

Balance Sheet

The company has $281.82 million in cash and $80.37 million in debt, giving a net cash position of $201.46 million or $3.20 per share.

Cash & Cash Equivalents	281.82M
Total Debt	80.37M
Net Cash	201.46M
Net Cash Per Share	$3.20
Equity / Book Value	211.54M
Book Value Per Share	3.36
Working Capital	233.04M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$104.83 million and capital expenditures -$286,002, giving a free cash flow of -$105.11 million.

Operating Cash Flow	-104.83M
Capital Expenditures	-286,002
Free Cash Flow	-105.11M
FCF Per Share	-$2.44

Full Cash Flow Statement

Margins

Gross margin is 97.13%, with operating and profit margins of -2,677.43% and -3,197.14%.

Gross Margin	97.13%
Operating Margin	-2,677.43%
Pretax Margin	-3,105.47%
Profit Margin	-3,197.14%
EBITDA Margin	-2,504.68%
EBIT Margin	-2,519.55%
FCF Margin	-2,047.23%

Dividends & Yields

Abivax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-18.70%
FCF Yield	-11.98%

Analyst Forecast

The average price target for Abivax is $32.00, which is 130.71% higher than the current price. The consensus rating is "Buy".

Price Target	$32.00
Price Target Difference	130.71%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	160.58%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Abivax has an Altman Z-Score of 2.11 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.11
Piotroski F-Score	1